Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
- 23 March 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Neurology
- Vol. 16 (4), 213-228
- https://doi.org/10.1038/s41582-020-0330-x
Abstract
Frontotemporal dementia (FTD) encompasses a spectrum of clinical syndromes characterized by progressive executive, behavioural and language dysfunction. The various FTD spectrum disorders are associated with brain accumulation of different proteins: tau, the transactive response DNA binding protein of 43 kDa (TDP43), or fused in sarcoma (FUS) protein, Ewing sarcoma protein and TATA-binding protein-associated factor 15 (TAF15) (collectively known as FET proteins). Approximately 60% of patients with FTD have autosomal dominant mutations in C9orf72, GRN or MAPT genes. Currently available treatments are symptomatic and provide limited benefit. However, the increased understanding of FTD pathogenesis is driving the development of potential disease-modifying therapies. Most of these drugs target pathological tau — this category includes tau phosphorylation inhibitors, tau aggregation inhibitors, active and passive anti-tau immunotherapies, and MAPT-targeted antisense oligonucleotides. Some of these therapeutic approaches are being tested in phase II clinical trials. Pharmacological approaches that target the effects of GRN and C9orf72 mutations are also in development. Key results of large clinical trials will be available in a few years. However, clinical trials in FTD pose several challenges, and the development of specific brain imaging and molecular biomarkers could facilitate the recruitment of clinically homogenous groups to improve the chances of positive clinical trial results.Keywords
This publication has 213 references indexed in Scilit:
- Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALSActa Neuropathologica, 2013
- Rapamycin Attenuates the Progression of Tau Pathology in P301S Tau Transgenic MicePLOS ONE, 2013
- A Pan‐European Study of theC9orf72Repeat Associated withFTLD: Geographic Prevalence, Genomic Instability, and Intermediate RepeatsHuman Mutation, 2012
- Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALSNeuron, 2011
- A harmonized classification system for FTLD-TDP pathologyActa Neuropathologica, 2011
- Neuropathological background of phenotypical variability in frontotemporal dementiaActa Neuropathologica, 2011
- Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and mutationActa Neuropathologica, 2011
- FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degenerationActa Neuropathologica, 2010
- Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesisActa Neuropathologica, 2010
- Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an updateActa Neuropathologica, 2009